Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBINED-HF: Ferric Carboxymaltose and Dapagliflozin in HFrEF
NCT06434025Phase 3Not yet recruiting
- Sponsor
- Hospital de Clínicas de Porto Alegre
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ferric carboxymaltose, dapagliflozin in heart failure with reduced ejection fraction (HFrEF), iron deficiency anemia (IDA), sponsored by Hospital de Clínicas de Porto Alegre. Planned start May 2024; status: not yet recruiting.
02
Drugs
ferric carboxymaltosedapagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT06434025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06434025.